Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, ottobre 24
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
OPKO Health Inc
OPK
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.63
N/A
Ult. Agg.: Oct 23, 7:17 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
OPKO Health Financials
OPKO Health (OPK) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Crude Oil Moves Higher; Charles Schwab Shares Fall After Q3 Results
U.S. stocks mixed: Dow gained 450+ points, S&P rose, Nasdaq slipped. Healthcare led gains; energy fell. Oil and gold climbed, Asian markets mostly
Avi Kapoor
PRO
OPKO Health Raises FY2026 Sales Guidance from $530.000M-$560.000M to $560.000M-$585.000M vs $534.899M Est
OPKO Health (NASDAQ:OPK) raises FY2026 sales outlook from $530.000 million-$560.000 million to $560.000 million-$585.000 million vs $534.899 million estimate.
Benzinga Newsdesk
PRO
OPKO Health Sees Q3 Sales $131.000M-$142.000M vs $134.650M Est
OPKO Health (NASDAQ:OPK) sees Q3 sales of $131.000 million-$142.000 million vs $134.650 million analyst estimate.
Benzinga Newsdesk
PRO
OPKO Health Q2 EPS $(0.01), Sales $163.500M Beat $131.233M Estimate
OPKO Health (NASDAQ:OPK) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. This is a 85.71 percent increase over losses of $(0.07) per share from the
Benzinga Newsdesk
PRO
OPKO Health Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $551.214M Est
OPKO Health (NASDAQ:OPK) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $551.214 million estimate.
Benzinga Newsdesk
PRO
OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est
OPKO Health (NASDAQ:OPK) sees Q2 sales of $127.000 million-$132.000 million vs $136.329 million analyst estimate.
Benzinga Newsdesk
